Free Trial
NASDAQ:RPHM

Reneo Pharmaceuticals Q3 2023 Earnings Report

Reneo Pharmaceuticals logo

Reneo Pharmaceuticals EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.60
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Reneo Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Reneo Pharmaceuticals Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Monday, November 13, 2023
Conference Call Time
7:00AM ET

Reneo Pharmaceuticals Earnings Headlines

Onkure Therapeutics Inc (OKUR)
Elon Warns “America Is Broke”. Trump’s Plan Inside.
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
See More Reneo Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Reneo Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reneo Pharmaceuticals and other key companies, straight to your email.

About Reneo Pharmaceuticals

Reneo Pharmaceuticals (NASDAQ:RPHM), a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

View Reneo Pharmaceuticals Profile

More Earnings Resources from MarketBeat